Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBO-CARE: Ibogaine vs Extended-Release Naltrexone in Opioid Use Disorder
NCT07871877Phase 2Not yet recruiting
- Start
- Jul 2027
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibogaine in opioid use disorder (OUD) (3 arms). Primary endpoints: Participants With One or More Treatment-Emergent Serious Adverse Events or Prespecified Adverse Events of Special Interest, Maximum Change From the Corresponding Pre-Dose Baseline in Fridericia-Corrected QT Interval and 4 more. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
ibogaine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07871877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871877.